Loviride Explained

Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR[2] and AVANTI[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

Notes and References

  1. Web site: Loviride . aidsmap.com . https://web.archive.org/web/20070927192511/http://www.aidsmap.com/cms1032278.asp . 2007-09-27 .
  2. Kroon ED, Wit FW . CAESAR Coordinating Committee . 10.1016/S0140-6736(97)04441-3 . Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial . The Lancet . 1997 . 349 . 9063 . 1413–1421 . 20008082 .
  3. Gatell J, Lange J, Gartland M . AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group . Antiviral Therapy . 4 . 2 . 79–86 . 1999 . 10682152 . 10.1177/135965359900400204 . 22443598 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Loviride".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.